Madrigal Pharmaceuticals, Inc. MDGL Total Current Liabilities
Total Current Liabilities at other companies
Other financials
Where this comes from
Reported directly by Madrigal Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:LiabilitiesCurrent.
The official record: Madrigal Pharmaceuticals, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Madrigal Pharmaceuticals, Inc.'s total current liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Madrigal Pharmaceuticals, Inc.'s total current liabilities?
- Madrigal Pharmaceuticals, Inc. (MDGL) reported total current liabilities of $338.26M in Q1 2026.
- How has Madrigal Pharmaceuticals, Inc.'s total current liabilities changed year-over-year?
- Madrigal Pharmaceuticals, Inc.'s total current liabilities increased by 102.3% year-over-year, from $167.24M to $338.26M.
- What is the long-term trend for Madrigal Pharmaceuticals, Inc.'s total current liabilities?
- Over 5 years (2020 to 2025), Madrigal Pharmaceuticals, Inc.'s total current liabilities has grown at a 46.1% compound annual growth rate (CAGR), from $46.56M to $310.29M.
- What does total current liabilities mean?
- Total debts the company must pay within one year.
- How do you interpret total current liabilities?
- A high ratio relative to current assets may indicate potential liquidity stress, especially for pre-revenue companies.
- How does total current liabilities compare across companies?
- Compared against current assets to determine the current ratio and short-term financial health.